Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice.

Nam DH, Lee MH, Kim JE, Song HK, Kang YS, Lee JE, Kim HW, Cha JJ, Hyun YY, Kim SH, Han SY, Han KH, Han JY, Cha DR.

Endocrinology. 2012 Mar;153(3):1387-96. doi: 10.1210/en.2011-1423. Epub 2012 Jan 10.

PMID:
22234468
2.

CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice.

Kang YS, Lee MH, Song HK, Ko GJ, Kwon OS, Lim TK, Kim SH, Han SY, Han KH, Lee JE, Han JY, Kim HK, Cha DR.

Kidney Int. 2010 Nov;78(9):883-94. doi: 10.1038/ki.2010.263. Epub 2010 Aug 4.

3.

Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice.

Cha JJ, Hyun YY, Lee MH, Kim JE, Nam DH, Song HK, Kang YS, Lee JE, Kim HW, Han JY, Cha DR.

Endocrinology. 2013 Jun;154(6):2144-55. doi: 10.1210/en.2012-2080. Epub 2013 Apr 8.

PMID:
23568555
4.

Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.

Kim HW, Lee JE, Cha JJ, Hyun YY, Kim JE, Lee MH, Song HK, Nam DH, Han JY, Han SY, Han KH, Kang YS, Cha DR.

Endocrinology. 2013 Sep;154(9):3366-76. doi: 10.1210/en.2012-2276. Epub 2013 Jul 3.

PMID:
23825123
5.

Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.

Jourdan T, Demizieux L, Gresti J, Djaouti L, Gaba L, Vergès B, Degrace P.

Hepatology. 2012 Mar;55(3):790-9. doi: 10.1002/hep.24733. Epub 2012 Jan 30.

PMID:
21987372
6.

Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.

Jourdan T, Szanda G, Rosenberg AZ, Tam J, Earley BJ, Godlewski G, Cinar R, Liu Z, Liu J, Ju C, Pacher P, Kunos G.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5420-8. doi: 10.1073/pnas.1419901111. Epub 2014 Nov 24.

7.

Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy.

Barutta F, Corbelli A, Mastrocola R, Gambino R, Di Marzo V, Pinach S, Rastaldi MP, Perin PC, Gruden G.

Diabetes. 2010 Apr;59(4):1046-54. doi: 10.2337/db09-1336. Epub 2010 Jan 12.

8.

Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.

Tam J, Godlewski G, Earley BJ, Zhou L, Jourdan T, Szanda G, Cinar R, Kunos G.

Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E457-68. doi: 10.1152/ajpendo.00489.2013. Epub 2013 Dec 31.

9.

Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy.

Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L, Liu BC.

Am J Physiol Endocrinol Metab. 2015 Jun 15;308(12):E1140-8. doi: 10.1152/ajpendo.00591.2014. Epub 2015 Apr 28.

10.

CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.

Jourdan T, Djaouti L, Demizieux L, Gresti J, Vergès B, Degrace P.

Diabetes. 2010 Apr;59(4):926-34. doi: 10.2337/db09-1482. Epub 2010 Jan 28.

11.

Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes.

Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, Vettor R, Pasquali R, Carruba MO, Marsicano G, Lutz B, Pagotto U, Nisoli E.

Diabetes. 2008 Aug;57(8):2028-36. doi: 10.2337/db07-1623. Epub 2008 May 13.

12.

Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages.

Miranville A, Herling AW, Biemer-Daub G, Voss MD.

Obesity (Silver Spring). 2010 Dec;18(12):2247-54. doi: 10.1038/oby.2010.81. Epub 2010 Apr 8.

13.

Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.

Bell-Anderson KS, Aouad L, Williams H, Sanz FR, Phuyal J, Larter CZ, Farrell GC, Caterson ID.

Int J Obes (Lond). 2011 Dec;35(12):1539-48. doi: 10.1038/ijo.2011.55. Epub 2011 Mar 8.

PMID:
21386801
14.

Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice.

Kim JE, Lee MH, Nam DH, Song HK, Kang YS, Lee JE, Kim HW, Cha JJ, Hyun YY, Han SY, Han KH, Han JY, Cha DR.

PLoS One. 2013 Apr 26;8(4):e62068. doi: 10.1371/journal.pone.0062068. Print 2013.

15.

NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.

Zhang L, Li R, Shi W, Liang X, Liu S, Ye Z, Yu C, Chen Y, Zhang B, Wang W, Lai Y, Ma J, Li Z, Tan X.

Br J Pharmacol. 2013 Sep;170(2):426-39. doi: 10.1111/bph.12292.

16.

PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, Guan Y.

Kidney Int. 2006 May;69(9):1511-7.

17.

The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase.

Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT, D'Esposito V, Beguinot F, Formisano P, Bifulco M.

Mol Pharmacol. 2008 Dec;74(6):1678-86. doi: 10.1124/mol.108.049205. Epub 2008 Sep 18.

18.

Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.

Chen W, Chen Z, Xue N, Zheng Z, Li S, Wang L.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Aug;386(8):721-32. doi: 10.1007/s00210-013-0875-y. Epub 2013 Apr 26.

PMID:
23620336
19.

The CB1 endocannabinoid system modulates adipocyte insulin sensitivity.

Motaghedi R, McGraw TE.

Obesity (Silver Spring). 2008 Aug;16(8):1727-34. doi: 10.1038/oby.2008.309. Epub 2008 Jun 12.

20.

Inhibition of cannabinoid CB1 receptor upregulates Slc2a4 expression via nuclear factor-κB and sterol regulatory element-binding protein-1 in adipocytes.

Furuya DT, Poletto AC, Freitas HS, Machado UF.

J Mol Endocrinol. 2012 Jul 25;49(2):97-106. doi: 10.1530/JME-12-0037. Print 2012 Oct.

PMID:
22735681

Supplemental Content

Support Center